# Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

> **NCT00303615** · PHASE2 · TERMINATED · sponsor: **Legacy Health System** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fluoxymesterone 10 mg
- **DRUG:** Anastrozole 1 mg

## Key facts

- **NCT ID:** NCT00303615
- **Lead sponsor:** Legacy Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low accrural
- **Last updated:** 2008-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303615, "Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00303615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*